[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
Identifieur interne : 000A29 ( Main/Merge ); précédent : 000A28; suivant : 000A30[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
Auteurs : L. Kochbati [Tunisie] ; H. Boussen ; F. Benna ; Z. Belhaj Ali ; A. Gammoudi ; N. Bouaouina ; M. Besbes ; L. Ghilen ; K. Rahal ; M. MaalejSource :
- Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [ 1278-3218 ] ; 2003.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Bléomycine (administration et posologie), Chlorméthine (effets indésirables), Dacarbazine (administration et posologie), Doxorubicine (administration et posologie), Enfant, Facteurs de risque, Femelle, Humains, Incidence, Maladie de Hodgkin (radiothérapie), Maladie de Hodgkin (traitement médicamenteux), Mâle, Prednisone (effets indésirables), Procarbazine (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Seconde tumeur primitive (épidémiologie), Seconde tumeur primitive (étiologie), Tunisie (épidémiologie), Vinblastine (administration et posologie), Vincristine (effets indésirables), Études rétrospectives.
- MESH :
- administration et posologie : Bléomycine, Dacarbazine, Doxorubicine, Protocoles de polychimiothérapie antinéoplasique, Vinblastine.
- effets indésirables : Chlorméthine, Prednisone, Procarbazine, Protocoles de polychimiothérapie antinéoplasique, Vincristine.
- radiothérapie : Maladie de Hodgkin.
- traitement médicamenteux : Maladie de Hodgkin.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- épidémiologie : Seconde tumeur primitive, Tunisie.
- étiologie : Seconde tumeur primitive.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Facteurs de risque, Femelle, Humains, Incidence, Mâle, Études rétrospectives.
- Wicri :
- geographic : Tunisie.
English descriptors
- KwdEn :
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bleomycin (administration & dosage), Child, Dacarbazine (administration & dosage), Doxorubicin (administration & dosage), Female, Hodgkin Disease (drug therapy), Hodgkin Disease (radiotherapy), Humans, Incidence, Male, Mechlorethamine (adverse effects), Middle Aged, Neoplasms, Second Primary (epidemiology), Neoplasms, Second Primary (etiology), Prednisone (adverse effects), Procarbazine (adverse effects), Retrospective Studies, Risk Factors, Tunisia (epidemiology), Vinblastine (administration & dosage), Vincristine (adverse effects).
- MESH :
- chemical , administration & dosage : Bleomycin, Dacarbazine, Doxorubicin, Vinblastine.
- chemical , adverse effects : Vincristine.
- geographic , epidemiology : Tunisia.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Mechlorethamine, Prednisone, Procarbazine.
- drug therapy : Hodgkin Disease.
- epidemiology : Neoplasms, Second Primary.
- etiology : Neoplasms, Second Primary.
- radiotherapy : Hodgkin Disease.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adolescent, Adult, Child, Female, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Risk Factors.
Abstract
To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.
PubMed: 14522350
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000072
- to stream PubMed, to step Curation: 000072
- to stream PubMed, to step Checkpoint: 000072
- to stream Ncbi, to step Merge: 000037
- to stream Ncbi, to step Curation: 000037
- to stream Ncbi, to step Checkpoint: 000037
Links to Exploration step
pubmed:14522350Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].</title>
<author><name sortKey="Kochbati, L" sort="Kochbati, L" uniqKey="Kochbati L" first="L" last="Kochbati">L. Kochbati</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de radiothérapie carcinologie, institut Salah-Azaïz, boulevard Bab-Saadoun 1006 Tunis, Tunisie. lofti.kochbati@rns.tn</nlm:affiliation>
<country xml:lang="fr">Tunisie</country>
<wicri:regionArea>Service de radiothérapie carcinologie, institut Salah-Azaïz, boulevard Bab-Saadoun 1006 Tunis</wicri:regionArea>
<wicri:noRegion>boulevard Bab-Saadoun 1006 Tunis</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boussen, H" sort="Boussen, H" uniqKey="Boussen H" first="H" last="Boussen">H. Boussen</name>
</author>
<author><name sortKey="Benna, F" sort="Benna, F" uniqKey="Benna F" first="F" last="Benna">F. Benna</name>
</author>
<author><name sortKey="Belhaj Ali, Z" sort="Belhaj Ali, Z" uniqKey="Belhaj Ali Z" first="Z" last="Belhaj Ali">Z. Belhaj Ali</name>
</author>
<author><name sortKey="Gammoudi, A" sort="Gammoudi, A" uniqKey="Gammoudi A" first="A" last="Gammoudi">A. Gammoudi</name>
</author>
<author><name sortKey="Bouaouina, N" sort="Bouaouina, N" uniqKey="Bouaouina N" first="N" last="Bouaouina">N. Bouaouina</name>
</author>
<author><name sortKey="Besbes, M" sort="Besbes, M" uniqKey="Besbes M" first="M" last="Besbes">M. Besbes</name>
</author>
<author><name sortKey="Ghilen, L" sort="Ghilen, L" uniqKey="Ghilen L" first="L" last="Ghilen">L. Ghilen</name>
</author>
<author><name sortKey="Rahal, K" sort="Rahal, K" uniqKey="Rahal K" first="K" last="Rahal">K. Rahal</name>
</author>
<author><name sortKey="Maalej, M" sort="Maalej, M" uniqKey="Maalej M" first="M" last="Maalej">M. Maalej</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14522350</idno>
<idno type="pmid">14522350</idno>
<idno type="wicri:Area/PubMed/Corpus">000072</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000072</idno>
<idno type="wicri:Area/PubMed/Curation">000072</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000072</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000072</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000072</idno>
<idno type="wicri:Area/Ncbi/Merge">000037</idno>
<idno type="wicri:Area/Ncbi/Curation">000037</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000037</idno>
<idno type="wicri:doubleKey">1278-3218:2003:Kochbati L:second:malignancies:following</idno>
<idno type="wicri:Area/Main/Merge">000A29</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].</title>
<author><name sortKey="Kochbati, L" sort="Kochbati, L" uniqKey="Kochbati L" first="L" last="Kochbati">L. Kochbati</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de radiothérapie carcinologie, institut Salah-Azaïz, boulevard Bab-Saadoun 1006 Tunis, Tunisie. lofti.kochbati@rns.tn</nlm:affiliation>
<country xml:lang="fr">Tunisie</country>
<wicri:regionArea>Service de radiothérapie carcinologie, institut Salah-Azaïz, boulevard Bab-Saadoun 1006 Tunis</wicri:regionArea>
<wicri:noRegion>boulevard Bab-Saadoun 1006 Tunis</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boussen, H" sort="Boussen, H" uniqKey="Boussen H" first="H" last="Boussen">H. Boussen</name>
</author>
<author><name sortKey="Benna, F" sort="Benna, F" uniqKey="Benna F" first="F" last="Benna">F. Benna</name>
</author>
<author><name sortKey="Belhaj Ali, Z" sort="Belhaj Ali, Z" uniqKey="Belhaj Ali Z" first="Z" last="Belhaj Ali">Z. Belhaj Ali</name>
</author>
<author><name sortKey="Gammoudi, A" sort="Gammoudi, A" uniqKey="Gammoudi A" first="A" last="Gammoudi">A. Gammoudi</name>
</author>
<author><name sortKey="Bouaouina, N" sort="Bouaouina, N" uniqKey="Bouaouina N" first="N" last="Bouaouina">N. Bouaouina</name>
</author>
<author><name sortKey="Besbes, M" sort="Besbes, M" uniqKey="Besbes M" first="M" last="Besbes">M. Besbes</name>
</author>
<author><name sortKey="Ghilen, L" sort="Ghilen, L" uniqKey="Ghilen L" first="L" last="Ghilen">L. Ghilen</name>
</author>
<author><name sortKey="Rahal, K" sort="Rahal, K" uniqKey="Rahal K" first="K" last="Rahal">K. Rahal</name>
</author>
<author><name sortKey="Maalej, M" sort="Maalej, M" uniqKey="Maalej M" first="M" last="Maalej">M. Maalej</name>
</author>
</analytic>
<series><title level="j">Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</title>
<idno type="ISSN">1278-3218</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Bleomycin (administration & dosage)</term>
<term>Child</term>
<term>Dacarbazine (administration & dosage)</term>
<term>Doxorubicin (administration & dosage)</term>
<term>Female</term>
<term>Hodgkin Disease (drug therapy)</term>
<term>Hodgkin Disease (radiotherapy)</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Mechlorethamine (adverse effects)</term>
<term>Middle Aged</term>
<term>Neoplasms, Second Primary (epidemiology)</term>
<term>Neoplasms, Second Primary (etiology)</term>
<term>Prednisone (adverse effects)</term>
<term>Procarbazine (adverse effects)</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Tunisia (epidemiology)</term>
<term>Vinblastine (administration & dosage)</term>
<term>Vincristine (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Bléomycine (administration et posologie)</term>
<term>Chlorméthine (effets indésirables)</term>
<term>Dacarbazine (administration et posologie)</term>
<term>Doxorubicine (administration et posologie)</term>
<term>Enfant</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Maladie de Hodgkin (radiothérapie)</term>
<term>Maladie de Hodgkin (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Prednisone (effets indésirables)</term>
<term>Procarbazine (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Seconde tumeur primitive (épidémiologie)</term>
<term>Seconde tumeur primitive (étiologie)</term>
<term>Tunisie (épidémiologie)</term>
<term>Vinblastine (administration et posologie)</term>
<term>Vincristine (effets indésirables)</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bleomycin</term>
<term>Dacarbazine</term>
<term>Doxorubicin</term>
<term>Vinblastine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Vincristine</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Tunisia</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Bléomycine</term>
<term>Dacarbazine</term>
<term>Doxorubicine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Vinblastine</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Mechlorethamine</term>
<term>Prednisone</term>
<term>Procarbazine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hodgkin Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Chlorméthine</term>
<term>Prednisone</term>
<term>Procarbazine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Neoplasms, Second Primary</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Neoplasms, Second Primary</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Hodgkin Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Maladie de Hodgkin</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Hodgkin</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Seconde tumeur primitive</term>
<term>Tunisie</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Seconde tumeur primitive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Child</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Mâle</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Tunisie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000A29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Terre |area= CobaltMaghrebV1 |flux= Main |étape= Merge |type= RBID |clé= pubmed:14522350 |texte= [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:14522350" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a CobaltMaghrebV1
![]() | This area was generated with Dilib version V0.6.32. | ![]() |